对于缺血性中风的ROA/ROCK,mTOR和分泌基治疗方法:新的视角
Elena Anca Pinoșanu1,2, Denisa Pîrșcoveanu1, Carmen Valeria Albu1
1Department of Neurology, University of Medicine and Pharmacy of Craiova, St. Petru Rares, No. 2-4, 200433 Craiova, Romania.
Current issues in molecular biology
|April 26, 2024
概括
本综述研究了RhoA/ROCK和mTOR信号通路作为缺血性中风的潜在治疗点. 针对这些途径在临床前模型中显示了神经保护作用,为中风恢复提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性中风通过复杂的细胞和分子事件引起显著的神经元损伤.
- 罗亚/ROCK和mTOR信号通路在缺血性脑损伤的病理生理学中起着至关重要的作用.
研究的目的:
- 审查针对缺血性中风中的RhoA/ROCK和mTOR信号通路的治疗策略.
- 探索针对这些途径的神经保护潜力,并讨论未来的研究方向.
主要方法:
- 文献综述侧重于中风模型中RhoA/ROCK和mTOR信号传导的临床前研究.
- 分析这些通路在细胞骨动力学,炎症,细胞生长,增殖和自中的作用.
主要成果:
- 针对RhoA/ROCK和mTOR途径在临床前中风模型中显示出神经保护作用.
- 挑战包括潜在的非目标效应和组织特定向的需要.
结论:
- 罗亚/ROCK和mTOR通路代表了缺血性中风的有希望的治疗点.
- 需要进一步的研究来阐明机制,优化治疗方法,并将研究结果转化为临床实践. 此外,MSC分泌体也显示出治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159